Veracyte Q2 revenue $72.9M (+32% YoY); net loss $9.5M, EPS -$0.13

VERACYTE, INC.

2022-Q2 EPS reported -$0.34 revenue$140,647,000

Revenue $72.9M, +32% YoY; testing $59.7M (+18%), biopharma $10.0M (vs $1.6M).
Test volume 24,904, +19% YoY; GAAP gross margin 59%, non-GAAP 66%.
Net loss $9.5M (+5% YoY), EPS -$0.13; non-GAAP op expenses $49.0M.
Cash and investments $164.0M at June 30; operating cash flow improved $29.4M YTD.
AUA/ASRO guideline now favorable for Decipher Prostate; multiple clinical data presentations at ASCO, ENDO, ESMO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.